Philip G. Bardin

Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials

Mario Castro, James Zangrilli, Michael E. Wechsler et al. · The Lancet Respiratory Medicine · 2015 · 1.2K citations

Life Sciences, Immunology, Pharmacotherapy +11

Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors from Editors of Respiratory, Sleep, and Critical Care Journals

David J. Lederer, Scott C. Bell, Richard D. Branson et al. · Annals of the American Thoracic Society · 2018 · 722 citations · Full text

Public Health, Biostatistics, Causal Inference +16

Immunolocalization of cytokines in the nasal mucosa of normal and perennial rhinitic subjects. The mast cell as a source of IL-4, IL-5, and IL-6 in human allergic mucosal inflammation.

Peter Bradding, I. Feather, Susan J. Wilson et al. · The Journal of Immunology · 1993 · 565 citations · Full text

Life Sciences, Immunology, Pathobiology +17

Lower Airways Inflammation during Rhinovirus Colds in Normal and in Asthmatic Subjects

David J. Fraenkel, Philip G. Bardin, Gwendolyn Sanderson et al. · American Journal of Respiratory and Critical Care Medicine · 1995 · 378 citations

Veterinary Medicine, Immunology, Infectious Diseases +15

Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial

William W. Busse, Eugene R. Bleecker, J Mark FitzGerald et al. · The Lancet Respiratory Medicine · 2018 · 311 citations

Pharmacy, Pharmacology, Pharmacotherapy +6